

### Antibiotic resistance is a serious and growing threat

Multi-drug resistant infections are an urgent public health crisis. A major concern is the gram-negative pathogens, *E. coli* and *Klebsiella* species—common causes of community and hospital-acquired urinary tract infections (UTIs). These pathogens can become resistant to nearly all fluoroquinolones, penicillins and cephalosporins rendering these treatments virtually ineffective.

### New oral treatments for UTIs are needed

Approximately 75% of UTIs are currently being treated with drugs that are becoming increasingly less effective. The FDA has warned against the use of fluoroquinolones in uncomplicated UTIs because they are associated with disabling and potentially permanent side effects.


**>2,000,000**  
antibiotic-resistant  
infections each year

**>23,000**  
deaths per year

**150 million**  
UTIs occur yearly  
worldwide

**\$6 billion**  
in healthcare costs

>25% Enterobacteriaceae fluoroquinolone resistance in UTIs in most populous regions of the U.S.\*



\*BD Insights Research Database from 379 facilities.

**The Infectious Diseases Society of America emphasizes that new, oral antibiotics that treat gram-negative infections are highest priority.**


### Oral sulopenem opportunity: 1 product, 2 settings

One product with use in two settings provides a clinical and cost-effective solution to physicians, payers, and patients.



#### COMMUNITY

An option for the treatment of uncomplicated infections when resistant bacteria are confirmed or suspected



#### HOSPITAL


An option to step down to oral from IV antibiotics allows earlier discharge or avoidance of hospital admission

**Antibiotics with both hospital and community usage have historically generated between \$1–3B in peak sales, with the oral formulation providing a majority of the value.**

## The Iterum Solution: Sulopenem

Sulopenem is the first and only oral and IV targeted-spectrum penem ( $\beta$ -lactam) antibiotic being developed for the treatment of infections caused by multi-drug resistant, gram-negative bacteria in both the hospital and community settings.

Three initial indications are planned for this novel antibiotic:



	Formulation	2H-2017	1H-2018	2H-2018	1H-2019	2H-2019
<b>Uncomplicated Urinary Tract Infections (uUTI)</b>						
Sulopenem etzadroxil-probenecid	Oral		SPA* received	PIVOTAL PHASE 3		
<b>Complicated Urinary Tract Infections (cUTI)</b>						
Sulopenem	IV		SPA* received	PIVOTAL PHASE 3		
Sulopenem etzadroxil-probenecid	Oral					
<b>Complicated Intra-abdominal Infections (cIAI)</b>						
Sulopenem	IV		SPA* received	PIVOTAL PHASE 3		
Sulopenem etzadroxil-probenecid	Oral					

\*Special Protocol Agreement (SPA).

TOP-LINE RESULTS

**We believe there is a significant addressable market for sulopenem in the U.S., with opportunity for ~11MM infections annually.**

## Iterum Therapeutics is committed to bringing sulopenem to market in 2020

- 1989-99** • Discovered by Pfizer Phase 1 and 2 clinical trials (IV)
- 2002-09** • Prodrugs invented. Phase 1 and 2 clinical trials (oral)
- 2015** • Iterum Therapeutics acquired global license
- 2016-17** • Qualified Infectious Disease Product (QIDP) received. Clinical trial and development program reinitiated
- 2018** • Special Protocol Agreement (SPA) received and Phase 3 clinical trials initiated for uUTI, cUTI, and cIAI
- 2019** • Phase 3 topline results. File NDA
- 2020** • Projected FDA approval and launch

## About Iterum Therapeutics plc

Iterum Therapeutics is a clinical-stage pharmaceutical company dedicated to developing anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens. Iterum Therapeutics is advancing its first compound sulopenem, a penem anti-infective compound with oral and IV formulations. Iterum Therapeutics has received QIDP designations for its oral and IV sulopenem formulations for the treatment of uUTI, cUTI and cIAI. The FDA has granted Special Protocol Agreements (SPA) for the Phase 3 trials of sulopenem in uUTI, cUTI and cIAI.

For more information, please visit <https://www.iterumtx.com>.

Iterum Therapeutics is a public company traded on the NASDAQ exchange under the symbol ITRM. This Company Overview is a summary of more detailed disclosure that can be found in filings made by Iterum Therapeutics with the U.S. Securities and Exchange Commission (SEC). Sulopenem is an investigational medication that has not been found by the U.S. Food and Drug Administration to be safe or effective for any indication. This Company Overview contains forward-looking statements within the meaning of U.S. federal securities laws, including statements about the anticipated effectiveness of sulopenem in treating infections in community-based and hospitalized patients, and the company's plans and timing for submitting a new drug application for sulopenem. These statements involve significant risks and uncertainties, discussion of which can be found under the caption "Risk Factors" in the final prospectus for Iterum Therapeutics' initial public offering, filed by the company with the SEC on May 25, 2018 and in other filings which the Company may make with the SEC in the future. The company's actual results may differ materially from those indicated in the forward-looking statements. The information in this fact sheet is given as of June 25, 2018. Except as required by law, Iterum Therapeutics specifically disclaims any obligation to update the information in this Company Overview. Iterum Therapeutics plc. All rights reserved.

## Senior Management

**Corey N. Fishman**  
Chief Executive Officer

**Michael Dunne, MD**  
Chief Scientific Officer

**Judith M. Matthews**  
Chief Financial Officer

## Board of Directors

**Paul R. Edick**  
Chairman at Iterum Therapeutics  
Chairman, President & CEO at Xeris Pharmaceuticals

**Corey N. Fishman**  
Chief Executive Officer at Iterum Therapeutics

**Brent Ahrens**  
General Partner at Cannan Partners

**Mark Chin**  
Investment Manager at Aris Bioscience

**James Healy, MD, PhD**  
General Partner at Sofinnova Ventures

**Patrick Heron**  
Managing General Partner at Frazier Healthcare Partners

**Ron Hunt**  
Managing Director at New Leaf Venture Partners

**David G. Kelly**  
Executive VP at Horizon Pharma, plc

**Shahzad Malik**  
General Partner at Advent Life Sciences

## Media Relations Contact:

[communications@iterumtx.com](mailto:communications@iterumtx.com)

**Corporate Headquarters** • Block 2 Floor 3, Harcourt Centre • Harcourt Street, Dublin 2

**US Operations** • 200 S Wacker Dr. • Suite 2550 Chicago, IL 60606

**R&D and Technical** • 20 Research Parkway Suite A • Old Saybrook, CT 06475

